Un Estudio Aleatorizado, Doble Ciego y Controlado Comparando NRX-101 frente a Placebo para Adultos en Tratamiento con Estimulación Magnética Transcraneal para Depresión Resistente al Tratamiento (SPARC-TMS)
Un Estudio Aleatorizado, Doble Ciego y Controlado que Compara NRX-101 frente a Placebo para Adultos en Tratamiento con Estimulación Magnética Transcraneal para la Depresión Resistente al Tratamiento
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative. Repetitive transcranial magnetic stimulation (rTMS) and more recently, theta-burst stimulation (TBS), are the noninvasive brain stimulation modalities with the largest evidence base in MDD. Although efficacious, an unacceptable proportion of patients do not significantly improve, and several aspects of the TMS parameter space are under investigation to enhance clinical outcomes.
This study will compare Rapid Robotically-guided Transcranial Magnetic Stimulation (RRTMS) combined with an investigational neuroplasticity-inducing medication (NRX-101) to the effects of (1) sham TMS treatment and (2) placebo in achieving clinical response and remission from depression in patients with Treatment Resistant Depression.
DCS has been shown in a randomized trial of more than double the percent response and remission from traditional TMS. When a one day (ONE-D) TMS protocol was combined with DCS, the measured response rate was 87% at one week.
This trial will compare response and remission at six weeks following neuronavigated robotic-enabled Transcranial Magnetic Stimulation + NRX-101 (D-cycloserine/lurasidone) vs. TMS+placebo.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative. Repetitive transcranial magnetic stimulation (rTMS) and more recently, theta-burst stimulation (TBS), are the noninvasive brain stimulation modalities with the largest evidence base in MDD. Although efficacious, an unacceptable proportion of patients do not significantly improve, and several aspects of the TMS parameter space are under investigation to enhance clinical outcomes.
Current treatments for Treatment Resistant Depression (TRD), such as oral antidepressants and conventional daily TMS, are limited. They require weeks of daily outpatient treatment, have modest response rates of 30-50%, and are not effective for many patients. In particular they are not generally suitable for military personnel, first responders, and others with demanding jobs. While some accelerated TMS protocols exist, there is no approved single-day treatment that provides a rapid and durable response. Furthermore, no existing treatments have leveraged the synergistic effect of combining TMS with a pharmacological agent that enhances its mechanism of action in a large-scale, FDA-pivotal trial.
The purpose the "Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS)" trial is to determine whether a single day of Rapid Robotically-controlled Transcranial Magnetic Stimulation (RRTMS) with robotic guidance can be effective in achieving clinical response and remission from depression. SPARC-TMS is a 240-patient, randomized controlled trial to establish the first validated single-day treatment for treatment-resistant depression (TRD). The project combines RRTMS with the investigational drug NRX-101 (a combination of D-cycloserine and lurasidone) that may have the effect of increasing the formation of new connections between brain cells (neuroplasticity).
The SPARC-TMS trial is funded by the United States Defense Advanced Research Projects Agency (DARPA) as part of the Strengthening Resilient Emotions and Nimble Cognition through Engineering Neuroplasticity (STRENGTHEN) program. https://www.darpa.mil/research/programs/strengthening-resilient-emotions The program recognizes that since September 11, 2001, more than 30,000 active duty members and veterans have taken their own lives - a tragic toll that represents four times the number of those killed in post-911 military operations. Developing effective approaches to prevent suicide is a top priority within the Department of Defense.
The SPARC-TMS protocol aims to demonstrate:
- Durability and Efficacy: Establishing a treatment that provides a long-lasting, robust antidepressant effect.
- Mechanism of Action: Gaining a deeper, mechanistic understanding of how this combination therapy works.
rTMS and TBS are believed to depend on synaptic plasticity in targeted circuits. Yet, there are several lines of evidence to suggest that synaptic plasticity is not intact in MDD, such as impaired learning and memory and lower expression of trophic factors.Using TMS as a tool to probe synaptic plasticity, individuals with MDD have reduced long-term potentiation-like facilitation in the motor cortex and prefrontal cortex. Importantly, this is observed with the intermittent TBS (iTBS) protocol used in MDD treatment. As such, iTBS treatment effects may be constrained by impaired synaptic plasticity in MDD.
One potential strategy to improve outcomes is to adjunctively target the N-methyl-D-aspartate (NMDA) receptor during stimulation, an ionotropic glutamate receptor and key regulator of synaptic plasticity.Synaptic plasticity with continuous and intermittent TBS is NMDA-receptor dependent, as antagonists abolish the effects of both protocols.We have shown that targeting the NMDA receptor with low doses of the partial agonist, D-cycloserine (DCS), normalizes long-term motor cortex plasticity in individuals with MDD. Moreover, it results in greater persistence of iTBS-induced changes compared with placebo.However, a demonstration that these physiological effects have an impact on treatment outcomes is needed
DCS has been shown in a randomized trial of more than double the percent response and remission from traditional TMS. When a one day (ONE-D) TMS protocol was combined with DCS, the measured response rate was 87% at one week.
This trial will compare response and remission at six weeks following neuronavigated robotic-enabled Transcranial Magnetic Stimulation + NRX-101 (D-cycloserine/lurasidone) vs. TMS+placebo.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
- Fase 3
Acceso ampliado
Acceso ampliado
Disponible
- Disponible: el acceso ampliado está actualmente disponible para este tratamiento en investigación, y los pacientes que no participan en el estudio clínico pueden obtener acceso al medicamento, producto biológico o dispositivo médico. en estudio.
- Ya no está disponible: el acceso ampliado estaba disponible para esta intervención anteriormente, pero no está disponible actualmente y no lo estará en el futuro.
- No disponible temporalmente: el acceso ampliado no está disponible actualmente para esta intervención, pero se espera que esté disponible en el futuro.
- Aprobado para marketing: la intervención ha sido aprobado por la Administración de Drogas y Alimentos de los EE. UU. para uso público.
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Martin Goodwin, PhD
- Número de teléfono: 18443977272
- Correo electrónico: mgoodwin@nrxdefense.com
Ubicaciones de estudio
-
-
Florida
-
Sarasota, Florida, Estados Unidos, 34239
- Reclutamiento
- HOPE Study Site
-
Contacto:
- Kimberly H Joffe, APRN, PMHNP
- Número de teléfono: 561-372-8705
- Correo electrónico: kjoffe@hopetherapeutics.com
-
Contacto:
- Rebecca Cohen, MD
- Número de teléfono: 18443977272
- Correo electrónico: rcohen@hopetherapeutics.com
-
West Palm Beach, Florida, Estados Unidos, 33417
- Reclutamiento
- HOPE Accelerated Care
-
Contacto:
- Rebecca Cohen, MD
- Número de teléfono: (941) 559-8500
- Correo electrónico: rcohen@hopetherapeutics.com
-
Contacto:
- Kimberly H Joffee, APRN, PMHNP
- Número de teléfono: 561-277-3088
- Correo electrónico: recruitment@hopetherapeutics.com
-
-
Massachusetts
-
Belmont, Massachusetts, Estados Unidos, 02478
- Reclutamiento
- Harvard Mclean Hospital
-
Contacto:
- Kerry Ressler, MD
- Número de teléfono: 617-855-4210
- Correo electrónico: kressler@mclean.harvard.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
18 to 65 years of age, inclusive, at Screening. 2. Participants must be initiating a new course of TMS treatment and must be TMS-naïve. 3. Able to understand and provide written and dated informed consent prior to Screening. 4. Deemed likely to comply with the study protocol, including communication of adverse events (AEs) and other clinically important information, including adherence to the text messaging component of the trial. 5. Previously diagnosed with major depressive disorder (MDD) according to the criteria defined in the DSM-5. 6. Has treatment-resistant MDD defined as failure to achieve an adequate response after at least two adequate antidepressant trials of different agents, each given at a therapeutic dose and for sufficient duration. 7. A total score ≥ 25 on the 10 items of the MADRS. 8. Has an identified reliable informant/care partner that is willing to provide information and/or supportive care as necessary. 9. If heterosexual female, a status of non-childbearing potential or use of an acceptable form of birth control per the following criteria, and agrees to continue use of the same method of birth control for the duration of study participation:
- Non-childbearing potential: physiologically incapable of becoming pregnant (i.e., permanently sterilized [status posthysterectomy, bilateral tubal ligation], or post-menopausal with last menses at least one year prior to Screening); or
- Childbearing potential, and meets the following criteria:
i. Must agree to use at least one highly effective method of birth control (methods which result in a failure rate of less than 1% per year when used consistently and correctly) during study participation. Examples of acceptable highly effective methods include established use of oral, injected, implanted, or intrauterine hormonal contraception; placement of an intrauterine device or intrauterine system; or a vasectomized partner with documented azoospermia; or true sexual abstinence that is the participant's usual and preferred lifestyle. ii. Negative urinary pregnancy test at Screening, confirmed by a second negative urinary pregnancy test at Day 1, prior to receiving study treatment. 10. Body mass index (BMI) between 18-40 kg/m2; BMI up to 45 kg/m2 is allowed with Medical Monitor review and approval. 11. If receiving concurrent psychotherapy, the type and frequency of the therapy (e.g., weekly or monthly) has been stable for at least 3 months prior to Screening and will remain stable for the duration of study participation. 12. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, benzodiazepines, maximum 2 mg daily, or trazodone) will be allowed if the therapy has been stable for at least 4-weeks prior to screening and will remain stable during the course of the patient's participation in the study. 13. Concurrent treatment with benzodiazepines is allowed up to a maximum dose 2 mg/daily used for anxiety if therapy has been stable relative to dose and schedule for at least 4 weeks prior to screening and if it is expected to remain stable during the course of the patient's participation in the study. Exclusion criteria: A patient is ineligible for inclusion in this study Heterosexual female of childbearing potential who is not willing to use one of the specified forms of birth control during the study. 2. Female who is pregnant (positive pregnancy test at Screening) or breastfeeding. 3. Active suicidality (without the intention to act) as evidenced by a score of >3 on the Columbia Suicide Severity Rating Scale. 4. Current DSM-5 diagnosis of moderate or severe substance use disorder (except marijuana or tobacco use disorder) within the 12 months prior to Screening. (Note: Substance use disorder cannot be the precipitant for study entry). 5. Current DSM-5 diagnosis of alcohol use disorder 6. A lifetime history of phencyclidine (PCP)/ketamine drug abuse 7. History of schizophrenia or schizoaffective disorder 8. History of anorexia nervosa, bulimia nervosa, eating disorder not otherwise specified (NOS), or other specified feeding and eating disorders (OSFED) within 3 years of Screening. 9. Has dementia, delirium, amnestic, or any other cognitive disorder. 10. Renal impairment defined as estimated glomerular filtration rate (eGFR) < 60 mL/min, calculated using the 2021 CKD-EPI creatinine equation (racefree). 11. Clinically significant hepatic impairment. Clinically significant hepatic impairment is defined as a history of chronic liver disease (e.g., cirrhosis, chronic hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis) or evidence at Screening of acute liver disease or impaired liver function (e.g., ALT or AST >3 × ULN, total bilirubin >2 × ULN) or in the opinion of the Investigator. 12. A clinically significant abnormality on the Screening physical examination that may affect safety or study participation, or that may confound interpretation of study results according to the study clinician. 13. Risk factors for neurocardiogenic syncope including history of syncope/ presyncope related to noxious stimuli, anxiety, micturation, or posture. 14. Co-morbidities as ascertained by medical history, physical examination (including measurement of vital signs), clinical laboratory evaluations, and electrocardiogram (ECG) which might interfere with compliance or the ability to assess efficacy or safety. 15. Diagnosis of moderate to severe heart disease or current episode of:
- Myocardial infarction within 1 year of Screening.
- Diagnosis of angina pectoris.
- Prolonged QTc interval, as measured by Fridericia's correction formula (QTcF) ≥450 msec at Screening for males or ≥ 470 msec for females on 2 of 3 measurements at least 15 minutes apart prior to randomization on Day 1. 16. Diagnosis of chronic lung disease, excluding asthma. 17. Lifetime history of any of the following: neurologic conditions with structural cerebral damage, traumatic brain injury, multiple sclerosis, surgical procedures involving the brain or meninges, meningoencephalitis, degenerative central nervous system (CNS) disorder (e.g., Alzheimer's Disease, Parkinson's Disease), mental retardation, stroke (ischemic or hemorrhagic), intracranial abscess, or any other disease/procedure/accident/intervention that, according to the clinician, is deemed associated with significant injury to, or malfunction of, the CNS. 18. History of epilepsy, personal history of seizure, family history of epilepsy or seizure in a first degree relative. 19. Diagnosis of parenchymal or leptomeningeal cancer.
Diabetes mellitus fulfilling any of the following criteria:
- Unstable diabetes mellitus defined as glycosylated hemoglobin (HbA1c) >8.0 percent at Screening.
- Admitted to the hospital for treatment of diabetes mellitus or diabetes mellitus-related illness in the past 12 weeks.
- Not under physician care for diabetes mellitus.
- Not on the same dose of oral hypoglycemic drug(s) and/or diet for the 4 weeks prior to Screening. 180645 180645 Protocol NRX101-011_ MIND1 V3.0 FINAL Pg. 8 NRX101-011 Protocol v3.0 9 Confidential
- Not on the same dose of oral thiazolidinediones (glitazones) for the 8 weeks prior to Screening. 21. Any current or past history of any physical condition which, in the opinion of the investigator, may put the patient at risk or interfere with study results interpretation. 22. On exclusionary concomitant psychotropic and non-psychotropic medications (see Section 9.5) 23. Prescribed more than one agent in each of the following categories at randomization:
a. Approved SSRIs. b. Approved serotonin and norepinephrine reuptake inhibitors (SNRIs). c. Approved tetracyclic antidepressants (TeCAs). 24. Currently prescribed oxcarbazepine or carbamazepine. 25. Exclusionary laboratory values or any other clinically significant abnormal laboratory result at Screening. Within normal limits (WNL) will be determined based on lab values of the local lab used. 26. Known allergies to lurasidone or Latuda®, cycloserine or Seromycin®, or the following excipients: mannitol, croscarmellose sodium, magnesium stearate, silicon dioxide, and/or hydroxypropylmethylcellulose (HPMC). 27. Participation in any clinical trial with an investigational drug or device within the past 3 months or planned concurrent study participation. 28. Study site personnel and/or persons employed by NRx Pharma, Inc., the Contract Research Organization (CRO), the investigator, or study site (i.e., permanent, temporary contract worker, or designee responsible for the conduct of the study), or an immediate family member (i.e., spouse, parent, child, or sibling [biological or legally adopted]) of such persons. Positive urine toxicity screening for use of any cocaine, opiates, nonprescribed amphetamines, or non-prescribed barbiturates. (Note: cannabinoids or marijuana use is not exclusionary, unless patient meets the DSM-5 criteria for cannabis withdrawal). 30. Patients with pacemakers and/or any implants including metal in the head except the mouth (cochlear implant, implanted brain stimulators, aneurysm clips) 31. Individuals with an intracranial lesion or increased intracranial pressure
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Transcranial Magnetic Stimulation plus NRX-101
Participants are treated with Robotic Rapid TMS plus NRX-101 175mg DCS/8.5mg Lurasidone once on day of treatment |
One Day TMS Protocol performed with the Zeta Surgical neuronavigated robotic-enabled system and the neurocare Apollo TMS Device 30 Theta burst pulses delivered as per protocol D-cycloserine 175mg + Lurasidone 8.5mg |
|
Comparador de placebos: Transcranial Magnetic Stimualtion
Participants are treated with Robotic Rapid TMSS plus placebo once on day of treatment |
One Day TMS Protocol performed with the Zeta Surgical neuronavigated robotic-enabled system and the neurocare Apollo TMS Device 30 Theta burst pulses delivered as per protocol An oral placebo capsule visually identical to NRX-101 |
|
Experimental: Sham TMS + NRX-101
Participants will be treated with Sham TMS (i.e. a TMS coil that does not deliver effective energy to the brain) + NRX-101 175mg DCS/8.5mg Lurasidone once on day of treatment |
D-cycloserine 175mg + Lurasidone 8.5mg An Apollo TMS device configured not to deliver effective energy to the brain |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
MADRS Depression
Periodo de tiempo: 6 weeks
|
Montgomery Asberg Depression Rating Scale Total Score |
6 weeks
|
|
CGI-SS Suicidality
Periodo de tiempo: 6 weeks
|
Clinical Global Impression Suicidality Scale |
6 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percent Response on MADRS
Periodo de tiempo: Six weeks
|
Percent Response from Depression |
Six weeks
|
|
Percent Remission from Depression on MADRS
Periodo de tiempo: Six weeks
|
Percent Remission from Depression |
Six weeks
|
|
Percent Remission from Suicidality on CGI-SS
Periodo de tiempo: Six weeks
|
Percent Remission from Suicidality |
Six weeks
|
|
PHQ-9 Depression Scale
Periodo de tiempo: 6 weeks
|
PHQ-9 Depression Scale |
6 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Silla de estudio: Jonathan Javitt, MD, MPH, NRx Defense Systems
- Investigador principal: Joshua Brown, MD, PhD, NRx Defense Systems
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- NRX101-011
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Marco de tiempo para compartir IPD
upon study inception
Criterios de acceso compartido de IPD
Protocol and ICF shared with all SAP and CSR upon signed confidentiality agreement
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .